CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

about

CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

Item

http://www.wikidata.org/entity/Q41547582

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

@en

type

Item

label

CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

@en

prefLabel

CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

@en

P1476

CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

@en

P2093

Joseph D Malaer

http://www.w3.org/2001/XMLSchema#string

Porunelloor A Mathew

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family

Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes

CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function

Cancer statistics, 2016

Up on the tightrope: natural killer cell activation and inhibition

2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes

Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs.

HLA class I recognition by killer cell Ig-like receptors.

Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily.

P304

1637-1641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28861320

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5574936

http://www.w3.org/2001/XMLSchema#string